-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Boehringer Ingelheim recently announced that the U.
If approved, spesolimab will become the first drug to treat the onset of GPP
spesolimab is a new type of humanized selective antibody that can block the activation of interleukin-36 receptor (IL-36R), which is a signaling pathway in the immune system that participates in the pathogenesis of a variety of autoimmune diseases Mechanisms, including GPP
In the European Union and the United States, spesolimab MAA and BLA are based on data from the 12-week Effisayil-1 trial